Humacyte Expands Commercial and Business Development Opportunities Through Realignment of Ex-U.S. Rights to Symvess®
Rhea-AI Summary
Humacyte (Nasdaq: HUMA) on April 24, 2026 realigned ex-U.S. commercial rights to Symvess through an amended distribution agreement with Fresenius Medical Care. The amendment grants Humacyte exclusive distribution rights outside the U.S., with Fresenius entitled to low-single-digit royalties on Humacyte's net non-U.S. sales. U.S. distribution terms remain unchanged. The realignment is intended to support Humacyte's planned international expansion, advance discussions with potential corporate partners for indication-specific and regional rights, and enable previously announced initiatives in the Kingdom of Saudi Arabia and Israel. For uses beyond the FDA-approved extremity vascular trauma indication, Symvess remains investigational and is not approved for sale by the FDA or other regulators.
Positive
- Exclusive ex-U.S. distribution rights to Symvess secured
- Positions Humacyte to pursue international partnerships and indication deals
- Supports planned commercial initiatives in Saudi Arabia and Israel
Negative
- Fresenius entitled to low-single-digit royalties on ex-U.S. net sales
- Symvess is investigational for uses beyond FDA-approved extremity vascular trauma
- International commercialization still contingent on partner negotiations and regulatory approvals
News Market Reaction – HUMA
In the Apr 24 session, HUMA declined 1.14%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 22 | Executive appointment | Positive | +8.6% | Appointment of Chief Commercial Officer to drive Symvess and platform rollout. |
| Apr 21 | Regulatory milestone | Positive | -4.2% | Israeli ministry accepts Symvess marketing application with defined review period. |
| Mar 27 | Earnings and update | Positive | -13.2% | Q4 and 2025 results with early Symvess revenue, funding, and trial timelines. |
| Mar 26 | Executive appointment | Positive | -5.4% | New SVP Business Development to expand collaborations and partnerships. |
| Mar 23 | Earnings date notice | Positive | +8.6% | Announcement of date and webcast for Q4 and year-end 2025 results. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent history shows frequent divergences where seemingly positive corporate or regulatory updates are followed by negative price reactions, especially around earnings and business development news.
Over the past month, HUMA reported several steps in building out Symvess commercialization and leadership. On Mar 26 and Apr 22, it added senior commercial and business development executives. It also announced Israeli acceptance of a Symvess marketing application and released Q4/2025 results with modest revenue and financing updates. Price reactions have been mixed, with both strong gains and notable selloffs following ostensibly constructive news. Today’s ex‑U.S. rights realignment fits this ongoing commercialization narrative.
Key Terms
acellular tissue engineered vessel medical
vascular injury repair medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
- Ex-U.S. rights realigned under amendment to distribution agreement with Fresenius Medical Care -
- Positions Humacyte to advance discussions with corporate partners regarding international and indication-specific rights to Symvess –
- Existing terms related to U.S. distribution of Symvess remain unchanged
DURHAM, N.C., April 24, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that it has realigned the ex-U.S. rights to Symvess (acellular tissue engineered vessel) through an amendment to its distribution agreement with Fresenius Medical Care (FME).
“We are pleased to have worked successfully with our long-time partner and largest shareholder Fresenius Medical Care, to realign the global rights to Symvess in a manner that benefits both companies and best enables Humacyte’s planned international expansion,” said Dr. Laura Niklason, CEO of Humacyte. “The restructuring of ex-U.S. commercial rights enables us to fully advance the commercial initiatives that we previously announced in the Kingdom of Saudi Arabia and Israel in vascular injury repair and other indications. In addition, we are now positioned to advance discussions with prospective corporate partners regarding international and indication-specific rights to Symvess. As amended, the distribution agreement now provides that Humacyte will have the exclusive rights to distribute Symvess outside the U.S., and FME will be entitled to low-single-digit royalties on our net sales of Symvess outside the U.S. Existing terms related to the U.S. remain unchanged.”
For uses other than the FDA approval in the extremity vascular trauma indication, Symvess is an investigational product and has not been approved for sale by the FDA or any other regulatory agency.
About Humacyte
Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues, advanced tissue constructs, and organ systems designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Humacyte’s Biologics License Application for the acellular tissue engineered vessel (ATEV) in the vascular trauma indication was approved by the FDA in December 2024. ATEVs are also currently in late-stage clinical trials targeting other vascular applications, including arteriovenous (AV) access for hemodialysis and peripheral artery disease (PAD). Preclinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte’s 6mm ATEV for AV access in hemodialysis was the first product candidate to receive the FDA’s Regenerative Medicine Advanced Therapy (RMAT) designation and has also received FDA Fast Track designation. Humacyte’s 6mm ATEV for urgent arterial repair following
extremity vascular trauma and for advanced PAD also have received RMAT designations. The ATEV received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense. For more information, visit www.Humacyte.com.
Forward-Looking Statements
This press release contains forward-looking statements that are based on beliefs and assumptions and on information currently available. In some cases, you can identify forward-looking statements by the following words: “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties, and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. Forward-looking statements in this press release include, but are not limited to, our plans and ability to commercialize Symvess (including commercial initiatives in the Kingdom of Saudi Arabia and Israel) and, if approved by regulatory authorities, our product candidates, successfully and on our anticipated timelines; the degree of market acceptance of and the availability of third-party coverage and reimbursement for Symvess and, if approved by regulatory authorities, our product candidates; our ability to manufacture Symvess and, if approved by regulatory authorities, our product candidates in sufficient quantities to satisfy our clinical trial and commercial needs; the anticipated benefits of our ATEVs relative to existing alternatives; our plans and ability to execute product development, process development and preclinical development efforts successfully and on our anticipated timelines; our ability to design, initiate and successfully complete clinical trials and other studies for our product candidates and our plans and expectations regarding our ongoing or planned clinical trials; the anticipated characteristics and performance of our ATEVs; the implementation of our business model and strategic plans for our business; our ability to execute and achieve the expected benefits of our cost-saving measures and whether our efforts will result in further actions or additional asset impairment charges that adversely affect our business; and the timing or likelihood of regulatory filings, acceptances and approvals. We cannot assure you that the forward-looking statements in this press release will prove to be accurate. These forward-looking statements are subject to a number of significant risks and uncertainties that could cause actual results to differ materially from expected results, including, among others, changes in applicable laws or regulations, the possibility that Humacyte may be adversely affected by other economic, business, competitive and/or reputational factors, and other risks and uncertainties, including those described under the header “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2025 filed by Humacyte with the SEC, and in future SEC filings. Most of these factors are outside of Humacyte’s control and are difficult to predict. Furthermore, if the forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. Except as required by law, we have no current intention of updating any of the forward-looking statements in this press release. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.
Humacyte Investor Contact:
Joyce Allaire
LifeSci Advisors LLC
+1-617-435-6602
jallaire@lifesciadvisors.com
investors@humacyte.com
Humacyte Media Contact:
Rich Luchette
Precision Strategies
+1-202-845-3924
rich@precisionstrategies.com
media@humacyte.com
